My INR is 1.4 while I am taking warfarin 3 mg daily; what should the new warfarin dose be?

Warfarin Dose Adjustment for INR 1.4 on 3 mg Daily

For an INR of 1.4 on warfarin 3 mg daily, increase the weekly dose by approximately 10–20%, which translates to raising the daily dose to 3.5 mg (or alternating 3 mg and 4 mg on different days to achieve a weekly increase). 1

Rationale for Dose Adjustment

• An INR of 1.4 is subtherapeutic for all standard indications (target range 2.0–3.0 for atrial fibrillation, venous thromboembolism, and most mechanical valves). 2, 3
• The magnitude of dose increase should be 10–20% of the total weekly dose to bring most patients back into therapeutic range without overshooting. 1
• A 3 mg daily dose equals 21 mg weekly; a 10–20% increase means adding 2–4 mg per week, which can be achieved by increasing to 3.5 mg daily (24.5 mg weekly, a 17% increase) or alternating 3 mg and 4 mg on different days. 1

Monitoring Plan After Dose Adjustment

• Recheck the INR in 3–7 days after any dose change to assess response and prevent prolonged subtherapeutic anticoagulation. 1, 3
• Continue weekly INR monitoring until two consecutive values fall within the therapeutic range (2.0–3.0). 1
• Once stable, gradually extend monitoring intervals to every 2–4 weeks, with a maximum of 4 weeks between tests in well-controlled patients. 3, 4

Investigation of Contributing Factors

• Identify and address reversible causes of subtherapeutic INR, including:
  • New medications that induce warfarin metabolism (e.g., rifampin, carbamazepine, phenytoin) 1
  • Increased dietary vitamin K intake (green leafy vegetables, nutritional supplements) 1
  • Poor medication adherence or missed doses 2
  • Acute diarrhea or malabsorption reducing warfarin absorption 1

Common Pitfalls to Avoid

• Do not make large dose increases (>20% weekly) in response to a single subtherapeutic INR, as warfarin's full anticoagulant effect takes 2–7 days to manifest due to the long half-life of factor II (prothrombin). 1, 3
• Do not continue the same 3 mg dose without adjustment, as an INR of 1.4 provides inadequate stroke and thromboembolism protection. 2
• Do not delay INR rechecking beyond 7 days after a dose increase, as this may allow prolonged subtherapeutic anticoagulation and increased thromboembolic risk. 1

Special Considerations for Asian Patients

• Asian patients often require lower maintenance doses (mean 3.3 mg daily to achieve INR 2.0–2.5 in Chinese cohorts), but an INR of 1.4 remains subtherapeutic regardless of ethnicity. 3
• Genetic polymorphisms in CYP2C9 and VKORC1 are more prevalent in Asian populations and may explain lower dose requirements, but dose adjustments should still be guided by measured INR rather than genotype alone. 3

Bridging Anticoagulation Consideration

• If the indication is high-risk (e.g., mechanical mitral valve, recent venous thromboembolism within 3 months, atrial fibrillation with prior stroke), consider bridging with low-molecular-weight heparin or unfractionated heparin until the INR reaches therapeutic range on two consecutive measurements. 1, 3
• Bridging is generally not required for lower-risk indications such as atrial fibrillation without prior stroke or remote venous thromboembolism (>3 months ago). 3